Literature DB >> 8242660

Sequential changes in MHC antigen expression induced by the v-Ki-ras oncogene.

R L Darley1, A G Morris.   

Abstract

A series of early-passage cell lines were transformed with the v-Ki-ras oncogene with the aim of examining the effect of an activated ras gene on the ability of these cells to express major histocompatibility complex (MHC) antigens. These cell lines were found to undergo multiple phenotypic changes upon transformation and subsequent proliferation. At early passage, the predominant effect of ras was an increased ability to express class II antigens when induced with interferon gamma (IFN gamma). For class I antigens, maximum levels of expression induced with IFN gamma were largely unaffected, however, decreased sensitivity to induction with this lymphokine was noted. With subsequent in vitro or in vivo passage, both class I and class II antigen inducibility was attenuated. The latter phenotypic change was found to be transferable by coculture, implicating a soluble IFN gamma antagonist. Conditioned media from ras-transformed cells treated to activate their latent transforming growth factor beta (TGF beta) content mediated similar changes in MHC antigen inducibility, suggesting that TGF beta may be involved in modulating MHC antigen expression in ras-transformed cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8242660     DOI: 10.1007/bf01526791

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  36 in total

Review 1.  The regulation and expression of MHC class I genes.

Authors:  B David-Watine; A Israël; P Kourilsky
Journal:  Immunol Today       Date:  1990-08

2.  Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma.

Authors:  N Ito; S Kawata; S Tamura; K Takaishi; Y Shirai; S Kiso; I Yabuuchi; Y Matsuda; M Nishioka; S Tarui
Journal:  Cancer Res       Date:  1991-08-01       Impact factor: 12.701

3.  Increased secretion of type beta transforming growth factor accompanies viral transformation of cells.

Authors:  M A Anzano; A B Roberts; J E De Larco; L M Wakefield; R K Assoian; N S Roche; J M Smith; J E Lazarus; M B Sporn
Journal:  Mol Cell Biol       Date:  1985-01       Impact factor: 4.272

4.  Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells.

Authors:  C W Czarniecki; H H Chiu; G H Wong; S M McCabe; M A Palladino
Journal:  J Immunol       Date:  1988-06-15       Impact factor: 5.422

5.  Characterization of the mouse transforming growth factor-beta 1 promoter and activation by the Ha-ras oncogene.

Authors:  A G Geiser; S J Kim; A B Roberts; M B Sporn
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

6.  Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors.

Authors:  R Derynck; D V Goeddel; A Ullrich; J U Gutterman; R D Williams; T S Bringman; W H Berger
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

7.  Suppression of MHC class I gene expression by N-myc through enhancer inactivation.

Authors:  M Lenardo; A K Rustgi; A R Schievella; R Bernards
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

8.  Distribution and modulation of the cellular receptor for transforming growth factor-beta.

Authors:  L M Wakefield; D M Smith; T Masui; C C Harris; M B Sporn
Journal:  J Cell Biol       Date:  1987-08       Impact factor: 10.539

9.  Transcripts for transforming growth factors in human breast cancer: clinical correlates.

Authors:  P Barrett-Lee; M Travers; Y Luqmani; R C Coombes
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

10.  Inducibility of class II major histocompatibility complex antigens by interferon gamma is associated with reduced tumorigenicity in C3H mouse fibroblasts transformed by v-Ki-ras.

Authors:  W J Bateman; R Fiera; N Matthews; A G Morris
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.